RU2019137430A - Нейротрофины для применения в лечении тугоухости - Google Patents
Нейротрофины для применения в лечении тугоухости Download PDFInfo
- Publication number
- RU2019137430A RU2019137430A RU2019137430A RU2019137430A RU2019137430A RU 2019137430 A RU2019137430 A RU 2019137430A RU 2019137430 A RU2019137430 A RU 2019137430A RU 2019137430 A RU2019137430 A RU 2019137430A RU 2019137430 A RU2019137430 A RU 2019137430A
- Authority
- RU
- Russia
- Prior art keywords
- use according
- ngf
- neurotrophin
- composition
- administered
- Prior art date
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 title claims 16
- 102000007072 Nerve Growth Factors Human genes 0.000 title claims 8
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 3
- 239000011859 microparticle Substances 0.000 claims 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 2
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 235000011187 glycerol Nutrition 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 230000010370 hearing loss Effects 0.000 claims 2
- 208000016354 hearing loss disease Diseases 0.000 claims 2
- 102000046917 human NGF Human genes 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 1
- 206010011903 Deafness traumatic Diseases 0.000 claims 1
- 208000016621 Hearing disease Diseases 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 101100404651 Mus musculus Ngf gene Proteins 0.000 claims 1
- 108090000742 Neurotrophin 3 Proteins 0.000 claims 1
- 102100029268 Neurotrophin-3 Human genes 0.000 claims 1
- 102000003683 Neurotrophin-4 Human genes 0.000 claims 1
- 108090000099 Neurotrophin-4 Proteins 0.000 claims 1
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 claims 1
- 206010033109 Ototoxicity Diseases 0.000 claims 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 206010061373 Sudden Hearing Loss Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000004880 explosion Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 239000003900 neurotrophic factor Substances 0.000 claims 1
- 229940032018 neurotrophin 3 Drugs 0.000 claims 1
- 229940097998 neurotrophin 4 Drugs 0.000 claims 1
- 231100000262 ototoxicity Toxicity 0.000 claims 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 1
- 239000004633 polyglycolic acid Substances 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17172659.9A EP3406259A1 (en) | 2017-05-24 | 2017-05-24 | Neurotrophins for use in the treatment of hearing loss |
| EP17172659.9 | 2017-05-24 | ||
| PCT/EP2018/063310 WO2018215414A1 (en) | 2017-05-24 | 2018-05-22 | Neurotrophins for use in the treatment of hearing loss |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019137430A true RU2019137430A (ru) | 2021-06-24 |
| RU2019137430A3 RU2019137430A3 (https=) | 2021-08-30 |
Family
ID=58772736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019137430A RU2019137430A (ru) | 2017-05-24 | 2018-05-22 | Нейротрофины для применения в лечении тугоухости |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200155647A1 (https=) |
| EP (2) | EP3406259A1 (https=) |
| JP (1) | JP2020520956A (https=) |
| KR (1) | KR20200011951A (https=) |
| CN (1) | CN110691607A (https=) |
| AU (1) | AU2018274589A1 (https=) |
| BR (1) | BR112019024504A2 (https=) |
| CA (1) | CA3062744A1 (https=) |
| IL (1) | IL270701A (https=) |
| RU (1) | RU2019137430A (https=) |
| WO (1) | WO2018215414A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021151013A1 (en) * | 2020-01-24 | 2021-07-29 | Otonomy, Inc. | Growth factor formulation for condition associated with otic event |
| WO2022221351A1 (en) * | 2021-04-13 | 2022-10-20 | Dompé Farmaceutici S.P.A. | Treatment of neuropathic corneal pain with ngf |
| EP4452267B1 (en) * | 2021-12-23 | 2025-04-23 | Cilcare Dev | 4-phenyl-tetrahydropyridine derivatives for treating hearing diseases |
| EP4316505A1 (en) * | 2022-08-05 | 2024-02-07 | Dompé farmaceutici S.p.a. | Intranasal administration of ngf for the treatment of sensorineural hearing loss |
| KR102851394B1 (ko) * | 2022-11-11 | 2025-09-04 | 단국대학교 천안캠퍼스 산학협력단 | 광반응성 하이드로젤을 이용한 분화유도인자 탑재 나노캡슐 |
| EP4501346A1 (en) * | 2023-08-04 | 2025-02-05 | Dompe' Farmaceutici S.P.A. | Method for the prevention of hearing loss induced by a platinum-based chemotherapy drug |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6225282B1 (en) * | 1996-01-05 | 2001-05-01 | Genentech, Inc. | Treatment of hearing impairments |
| US5929041A (en) * | 1996-02-23 | 1999-07-27 | Amgen Inc. | Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product |
| US6113947A (en) * | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
| ES2213861T3 (es) | 1998-10-09 | 2004-09-01 | Scil Proteins Gmbh | Procedimiento de obtencion de ngf-beta activa. |
| US7700111B2 (en) * | 2002-01-17 | 2010-04-20 | The Regents Of The University Of Michigan | Auditory nerve protection and re-growth |
| WO2009062149A1 (en) * | 2007-11-08 | 2009-05-14 | Creighton University | Methods for maintaining inner ear neurons |
| EP2907521B1 (en) | 2011-12-19 | 2017-11-22 | Wacker Chemie AG | Novel prongf mutants and uses thereof in the production of beta-ngf |
| KR20180037994A (ko) * | 2015-07-28 | 2018-04-13 | 오토노미, 인코포레이티드 | TrkB 또는 TrkC 아고니스트 조성물 및 귀 병태의 치료 방법 |
| US10066229B2 (en) * | 2015-07-28 | 2018-09-04 | Otonomy, Inc. | Treatment using truncated Trk B and Trk C antagonists |
-
2017
- 2017-05-24 EP EP17172659.9A patent/EP3406259A1/en not_active Withdrawn
-
2018
- 2018-05-22 EP EP18725242.4A patent/EP3630159A1/en not_active Withdrawn
- 2018-05-22 US US16/615,201 patent/US20200155647A1/en not_active Abandoned
- 2018-05-22 JP JP2019564510A patent/JP2020520956A/ja active Pending
- 2018-05-22 CA CA3062744A patent/CA3062744A1/en active Pending
- 2018-05-22 KR KR1020197035948A patent/KR20200011951A/ko not_active Ceased
- 2018-05-22 AU AU2018274589A patent/AU2018274589A1/en not_active Abandoned
- 2018-05-22 WO PCT/EP2018/063310 patent/WO2018215414A1/en not_active Ceased
- 2018-05-22 BR BR112019024504-9A patent/BR112019024504A2/pt not_active IP Right Cessation
- 2018-05-22 RU RU2019137430A patent/RU2019137430A/ru unknown
- 2018-05-22 CN CN201880033628.8A patent/CN110691607A/zh active Pending
-
2019
- 2019-11-17 IL IL270701A patent/IL270701A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3406259A1 (en) | 2018-11-28 |
| CN110691607A (zh) | 2020-01-14 |
| BR112019024504A2 (pt) | 2020-06-23 |
| WO2018215414A1 (en) | 2018-11-29 |
| RU2019137430A3 (https=) | 2021-08-30 |
| CA3062744A1 (en) | 2018-11-29 |
| US20200155647A1 (en) | 2020-05-21 |
| JP2020520956A (ja) | 2020-07-16 |
| EP3630159A1 (en) | 2020-04-08 |
| AU2018274589A1 (en) | 2019-11-28 |
| IL270701A (en) | 2020-01-30 |
| KR20200011951A (ko) | 2020-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019137430A (ru) | Нейротрофины для применения в лечении тугоухости | |
| MX2021002321A (es) | Nuevos metodos. | |
| CR20210271A (es) | Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso | |
| JP2020520956A5 (https=) | ||
| RU2016144479A (ru) | Фармацевтические композиции для лечения заболеваний, опосредопосредованных муковисцидозным трансмембранным регулятором проводимости | |
| JP2018520189A5 (https=) | ||
| HRP20210543T1 (hr) | Inhibitori pde9 s imidazo triazinonskom okosnicom i imidazo pirazinonskom okosnicom za liječenje perifernih bolesti | |
| RU2006138153A (ru) | Способы лечения шума в ушах, индуцированного улитковой экситотоксичностью | |
| IL270395B (en) | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil | |
| IL307992A (en) | Parasitic formulations containing isoxazoline and methods for treating blepharitis | |
| WO2015048188A8 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| WO2018140792A3 (en) | Neurotrophin mutants for treating hearing loss and other otic disorders | |
| CL2020001791A1 (es) | Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas. | |
| PH12019500516A1 (en) | Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof | |
| BR112023019795A2 (pt) | Composições nasais compreendendo alcaftadina | |
| WO2017152129A3 (en) | Treatment of glaucoma and/or retinal diseases and formulations useful therefore | |
| RU2017112748A (ru) | Композиции онапристона пролонгированного действия и способы | |
| WO2015183984A3 (en) | Therapeutic compositions including tocopherol and uses thereof | |
| CO2024002715A2 (es) | Formulaciones de radiprodil | |
| WO2015183985A3 (en) | Therapeutic compositions including naphthoquinones and uses thereof | |
| MX2017012999A (es) | Acido pirrolidona carboxilico (pca) para uso oftalmico. | |
| Worsøe et al. | Intratympanic steroid prevents long-term spiral ganglion neuron loss in experimental meningitis | |
| JP2016504390A5 (https=) | ||
| US20220249432A1 (en) | Baicalein analogs for use in neuroprotection and regulation of immune reactivity | |
| RU2015140501A (ru) | Фармацевтические композиции на основе донепезила, характеризующиеся специфическим профилем растворимости in vitro или фармакокинетическими параметрами |